Yes‐associated protein activation potentiates glycogen synthase kinase‐3 inhibitor‐induced proliferation of neonatal cardiomyocytes and iPS cell‐derived cardiomyocytes. Issue 5 (21st March 2022)

• Record Type: Journal Article
• Authors: Kametani, Yusuke; Tanaka, Shota; Wada, Yuriko; Suzuki, Shota; Umeda, Ayaka; Nishinaka, Kosuke; Okada, Yoshiaki; Maeda, Makiko; Miyagawa, Shigeru; Sawa, Yoshiki; Obana, Masanori; Fujio, Yasushi
• Is Part Of: Journal of cellular physiology. Volume 237:Issue 5(2022)
• Page Start: 2539
• Page End: 2549
• Publication Date: 2022-03-21
• Subjects: cardiomyocyte -- catenins -- cell proliferation -- regeneration -- signal transduction; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.30724
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: Because mammalian cardiomyocytes largely cease to proliferate immediately after birth, the regenerative activity of the heart is limited. To date, much effort has been made to clarify the regulatory mechanism of cardiomyocyte proliferation because the amplification of cardiomyocytes could be a promising strategy for heart regenerative therapy. Recently, it was reported that the inhibition of glycogen synthase kinase (GSK)‐3 promotes the proliferation of neonatal rat cardiomyocytes (NRCMs) and human iPS cell‐derived cardiomyocytes (hiPSC‐CMs). Additionally, Yes‐associated protein (YAP) induces cardiomyocyte proliferation. The purpose of this study was to address the importance of YAP activity in cardiomyocyte proliferation induced by GSK‐3 inhibitors (GSK‐3Is) to develop a novel strategy for cardiomyocyte amplification. Immunofluorescent microscopic analysis using an anti‐Ki‐67 antibody demonstrated that the treatment of NRCMs with GSK‐3Is, such as BIO and CHIR99021, increased the ratio of proliferative cardiomyocytes. YAP was localized in the nuclei of more than 95% of cardiomyocytes, either in the presence or absence of GSK‐3Is, indicating that YAP was endogenously activated. GSK‐3Is increased the expression of β‐catenin and promoted its translocation into the nucleus without influencing YAP activity. The knockdown of YAP using siRNA or pharmacological inhibition of YAP using verteporfin or CIL56 dramatically reduced GSK‐3I‐induced cardiomyocyte proliferation without suppressing β‐catenin activation. Interestingly, the inhibition of GSK‐3 also induced the proliferation of hiPSC‐CMs under sparse culture conditions, where YAP was constitutively activated. In contrast, under dense culture conditions, in which YAP activity was suppressed, the proliferative effects of GSK‐3Is on hiPSC‐CMs were not detected. Importantly, the activation of YAP by the knockdown of α‐catenin restored the proproliferative activity of GSK‐3Is. Collectively, YAP activation potentiates the GSK‐3I‐induced proliferation of cardiomyocytes. The blockade of GSK‐3 in combination with YAP activation resulted in remarkable amplification of cardiomyocytes. Abstract : GSK‐3 inhibitors (GSK‐3Is) induce cardiomyocyte proliferation via β‐catenin. The activation of YAP potentiates GSK‐3I‐induced proliferation without modulating β‐catenin signaling. The blockade of GSK‐3 in combination with YAP activation could be a promising strategy for the amplification of cardiomyocytes.